Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.71 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906234 | 0.86 | MAPK8 (0.61) | PTGER4 | |
| SCHEMBL7181929 | 0.85 | PTGER4 (0.84) | PTGER4PTGER2L3MBTL1LIPGMAPT | |
| SCHEMBL4450413 | 0.84 | PTGER4 (0.81) | PTGER4PTGER2LIPGMAPTTHRB | |
| SCHEMBL4085505 | 0.83 | PTGER4 (0.77) | PTGER4PTGER2LIPGMAPTTHRB | |
| Hydrochloric Acid SCHEMBL6908368 | 0.83 | PTGER4 (0.77) | PTGER4PTGER2L3MBTL1LIPGMAPT | |
| SCHEMBL4450937 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2CYP3A4MAPK14 | |
| SCHEMBL8350630 | 0.83 | L3MBTL1 (0.52) | PTGER4PTGER2L3MBTL1NAMPTMAPT | |
| SCHEMBL13954366 | 0.82 | PTGER4 (0.76) | PTGER4PTGER2L3MBTL1LIPGMAPT | |
| SCHEMBL4087663 | 0.82 | PTGER4 (0.74) | PTGER4PTGER2L3MBTL1LIPGMAPT | |
| SCHEMBL4092310 | 0.82 | PTGER4 (0.81) | PTGER4PTGER2L3MBTL1LIPGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476157-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6756392-B2 | CARBOCYCLIC SECONDARY AMIDES SUCH AS 2-(4-FLUORO-PHENOXY) -N-(4-((2-HYDROXY-3-METHYL-BENZOYL AMINO)-METHYL)-BENZYL)-NICOTINAMIDE, ADMINISTERED FOR PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS | PFIZER INC | 2004-06-29 | — | — | US | disclosed |
| US-20030195233-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | MAGEE THOMAS V (US) | 2003-10-16 | — | — | US | disclosed |
| US-20030191158-A1 | Antiinflamamtory agents; antiallergens | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003068232-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068232-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195233-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PTGER4 49/4885PTGER2 710/4885L3MBTL1 4491/4885 |
| US-20030191158-A1 | Antiinflamamtory agents; antiallergens | NNMT, IL5, HNMT | PTGER4 290/4885PTGER2 775/4885L3MBTL1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.